Psychemedics (PMD) Proxy Filing summary

Executive summary

• Annual meeting will vote on director re-election, executive compensation, auditor ratification, a reverse/forward stock split, and a stock purchase agreement to facilitate deregistration and delisting from Nasdaq.

• The transaction aims to reduce public company costs, estimated at $900,000 annually, and streamline operations by going private.

• Stockholders with fewer than 4,000–6,000 shares will be cashed out at $2.35 per share; others retain their holdings post-split.

• The board and an independent transaction committee determined the transaction is fair, supported by a third-party fairness opinion.

• The company has explored strategic alternatives, including a sale, but found going private to be the best option.

Voting matters and shareholder proposals

• Proposals include director election, advisory vote on executive compensation, auditor ratification, reverse/forward stock split, ratification of the stock purchase agreement, and potential adjournment to solicit more proxies.

• Approval of the transaction proposals is required for the stock split and deregistration to proceed.

• The board recommends voting in favor of all proposals.

Board of directors and corporate governance

• The board consists of five members, four of whom are independent; all are nominated for re-election.

• The board has audit, compensation, and nominating/governance committees, all composed of independent directors.

• The board conducts annual self-evaluations and maintains a code of ethics.

• Board diversity is tracked and disclosed per Nasdaq requirements.

• The board leadership structure separates the roles of chairman and CEO.